Koios Care Funding News -Belgium HealthTech Startup Koios Care Secures €1M Funding To Monitor And Treat Parkinson’s Disease

The company uses an AI-powered platform that passively collects data from smartphones and smartwatches, offering continuous insights without disrupting patients' lives.

The funding round was led by Greek early-stage DeepTech investor Evercurious VC, with support from Astylab Ventures, the imec.istart fund, and angel investors coordinated by HeBAN.

Read Also - Denmark Clean Tech Startup Hymeth Secures €3.7M To Support Commercial Rollout Of Its Green Hydrogen System

With this funding, Koios Care plans to expand its digital health tool ‘Parkiwatch’ to more clinics across Europe, advance its regulatory approval, and deepen collaborations with pharma companies and research institutions.

“There’s a significant gap between what people with Parkinson’s truly need and what they currently receive. It’s not just about managing symptoms, it’s about meaningfully improving their overall Quality of Life. That’s the gap Koios Care is here to close,” said Dr Konstantinos Kyritsis, Co-founder and CEO “One patient using the technology to clearly communicate with their neurologist told us, ‘Sometimes, on my current medication scheme, it feels like I have no Parkinson’s.’ That’s not just encouraging, it’s a powerful glimpse of what’s possible. It’s the kind of transformation we are relentlessly working to deliver for everyone living with this disease.”

Koios Care, founded by Dr. Konstantinos Kyritsis and Dr. Dimitris Iakovakis, is transforming how neurological disorders like Parkinson’s Disease are monitored and treated.

Their AI-powered platform uses data collected passively from smartphones and smartwatches to give doctors real-world insights—moving beyond the limitations of occasional clinic visits and patient self-reporting.

The platform helps care teams make earlier, more personalized decisions using continuous, objective data. Koios Care is tackling what it calls a “silent pandemic” — the fast-growing number of Parkinson’s cases globally, now affecting over 10 million people.

By turning everyday devices into powerful health monitors, the company aims to improve care for patients, ease clinical workflows, and support better drug development. For doctors and patients, Koios provides a digital tool for ongoing treatment decisions. For pharmaceutical and MedTech companies it serves as a research platform offering real-world data and valuable insights for clinical trials.

“For too long, patients, clinicians and researchers have lacked continuous, objective data to truly personalise Parkinson’s care and understand the real-life impact of the disease and its treatments,” said Dr Iakovakis, Co-founder and CTO of Koios Care. “This funding reflects the urgent need for a new standard in care. With our solution, we empower patients to better understand their condition, equip medical teams with unprecedented insights, and provide pharmaceutical companies with a powerful tool to accelerate the development of more effective therapies.”

Koios Care has already studied 130 patients through a multi-centre EU clinical trial and is actively collaborating with hospitals and industry partners across Europe.

The platform is built to meet current regulatory standards for digital health tools and aims to enhance treatment decisions and increase clinical trial success by capturing real-world patient outcomes.

Alex Vamvakas, partner at Evercurious VC, commented, “Koios Care’s innovative approach to passively monitoring Quality of Life with everyday devices is a game-changer for neurodegenerative disorders. We are impressed by the team’s scientific rigor, the clinical validation and the vision to reshape long-term neurodegenerative conditions’ care and enable the shift toward personalised, data-driven disease management at scale.

“With roots in Greece and Belgium, and collaborators across Europe, Koios Care exemplifies the kind of region bridging, discipline spanning, impact-driven innovation that a more connected European DeepTech ecosystem can unlock. It reflects a vision of Europe where scientific excellence and entrepreneurial ambition transcend borders to solve pressing global challenges.”

Looking ahead, Koios Care aims to create drug-device combination products and extend its technology to other brain and behavior-related conditions such as Mild Cognitive Impairment, Alzheimer’s, narcolepsy, and eating disorders. The company is focused on areas where real-time, real-world data is still a key gap in both care and research.

About Koios Care

Founded in 2022, Koios Care uses everyday devices to gather accurate and useful neuroscience data. The platform helps patients take charge of their health, supports doctors in making better treatment decisions, and provides strong evidence for pharmaceutical research. Koios is already making a difference in hundreds of lives and is working with top pharma partners to improve neurological care.